Brief Report: Tolerability of COVID-19 Vaccines, BNT162b2 and mRNA-1273, in Patients with Thymic Epithelial Tumors

CONCLUSIONS: Tolerability of COVID-19 mRNA vaccines in patients with TETs is comparable to the general population. Most patients with pre-existing AD did not experience disease flares and the development of new AD was rare. Patients with TETs should be encouraged to get vaccinated against COVID-19 due to the documented benefits of vaccination and manageable risk profile.PMID:34514444 | PMC:PMC8423742 | DOI:10.1016/j.jtocrr.2021.100229

Source: Clinical Lung Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Madison Ballman Shannon Swift Cristina Mullenix Yvonne Mallory Chen Zhao Eva Szabo Meenakshi Shelat Susan Sansone Seth M Steinberg Meredith J McAdams Arun Rajan Source Type: research